Ultragenyx Pharmaceutical (RARE) Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RARE shares.
View RARE analyst ratings or view top-rated stocks.

11 Wall Street research analysts have issued 1 year price objectives for Ultragenyx Pharmaceutical's stock. Their RARE share price forecasts range from $47.00 to $133.00. On average, they expect the company's share price to reach $81.21 in the next twelve months. This suggests a possible upside of 122.9% from the stock's current price.
View analysts price targets for RARE or view top-rated stocks among Wall Street analysts.

Ultragenyx Pharmaceutical's stock was trading at $46.33 at the beginning of 2023. Since then, RARE shares have decreased by 21.4% and is now trading at $36.43.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our RARE earnings forecast.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced its earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($2.25) EPS for the quarter, missing the consensus estimate of ($2.11) by $0.14. The biopharmaceutical company earned $108.30 million during the quarter, compared to analysts' expectations of $107.10 million. Ultragenyx Pharmaceutical had a negative net margin of 178.91% and a negative trailing twelve-month return on equity of 220.54%. The company's revenue was up 21.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($2.26) earnings per share.

ETFs with the largest weight of Ultragenyx Pharmaceutical (NASDAQ:RARE) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Virtus LifeSci Biotech Products ETF (BBP), Motley Fool Small-Cap Growth ETF (TMFS), Motley Fool Mid-Cap Growth ETF (TMFM), MFAM Small-Cap Growth ETF (MFMS), WisdomTree BioRevolution Fund (WDNA) and SPDR S&P Biotech ETF (XBI).

Ultragenyx Pharmaceutical updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $425.00 million-$450.00 million, compared to the consensus revenue estimate of $437.55 million.

41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Ultragenyx Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.09%), Clearbridge Investments LLC (3.87%), Sands Capital Management LLC (3.74%), State Street Corp (3.45%), Alliancebernstein L.P. (2.12%) and Rock Springs Capital Management LP (1.94%). Insiders that own company stock include Camille L Bedrosian, Camille L Bedrosian, Corazon (Corsee) D Sanders, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, S Robson Walton, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski.
View institutional ownership trends.

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RARE stock can currently be purchased for approximately $36.43.

Ultragenyx Pharmaceutical (NASDAQ:RARE) has a market capitalization of $2.60 billion and generates $363.33 million in revenue each year. The biopharmaceutical company earns $-707,420,000.00 in net income (profit) each year or ($10.24) on an earnings per share basis.

The company employs 1,311 workers across the globe.

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The official website for the company is www.ultragenyx.com. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at ir@ultragenyx.com, or via fax at 415-483-8810.